Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT03323034 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT03323034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03323034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
January 11, 2018
Completion date
September 30, 2024
Enrollment
30 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent lymphoma, recurrent malignant solid neoplasm, recurrent primary central nervous system neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory primary central nervous system neoplasm